A non-disclosure agreement (NDA), also known as a confidentiality agreement, establishes contractual duties concerning information disclosed between parties. It can prevent unauthorized disclosure, onward transfer and use of information received during negotiations or a business relationship. For a foreign company sharing technical or commercial information with a person or business in Israel, an NDA can help define the permitted use of the information before the broader transaction has been agreed.
An NDA is a contractual safeguard. It should be distinguished from the statutory protection available to qualifying trade secrets under Israeli law. The two forms of protection may operate together, but they do not have identical requirements or bind the same persons.
When is a non-disclosure agreement needed?
An NDA is particularly relevant when non-public commercial information must be disclosed in connection with negotiations, product development, investment due diligence, technical consulting or a proposed collaboration. Under Section 5 of Israel’s Commercial Torts Law, 5759-1999, the protection of a trade secret depends, among other requirements, on the information remaining confidential and its owner taking reasonable steps to safeguard it. Unlike a patent or registered design, a trade secret is not protected through a registration procedure. The statutory requirements are discussed in our guide to trade secret protection in Israel.
Confidentiality also matters when the information could form the basis of a patent application or design protection. Disclosure before filing may affect the ability to obtain registered rights, depending on the relevant jurisdiction, the nature of the disclosure and any applicable exceptions. An NDA helps establish the circumstances in which a recipient was allowed to see the material; it does not replace an appropriate filing strategy.
Two circumstances are especially common.
Disclosure to technical professionals. An inventor or technology company may need to share an early-stage idea with an engineer, industrial designer, draftsman, software developer or consultant to develop the concept or prepare a prototype. Disclosure without adequate confidentiality arrangements may raise questions about prior publication and future patentability, as well as the risk of unauthorized use by the recipient. The Israeli dispute known as Meteor v. Polysack is referred to in the original discussion of these risks. Confidentiality and the scope of permitted work should be addressed before the technical information is provided.
Disclosure of a U.S. provisional patent application. A provisional application is not published by the USPTO as a standalone application and may never be followed by a nonprovisional or international application. A company may nevertheless need to show its contents to a potential investor, manufacturer or commercial partner. If no qualifying follow-on application is filed within the applicable period, generally 12 months for claiming priority, the applicant may lose the ability to rely on the provisional filing date for the disclosed subject matter. An earlier public disclosure could then create additional patentability problems. Failure to file a follow-on application within 12 months does not, by itself, make information that remains confidential available to the public. The confidentiality of the disclosure, any contractual obligations and the continued existence of a trade secret must be considered separately.
What are the limits of an NDA under Israeli law?
The principal limitation of an NDA is that its contractual obligations bind the parties who undertake them. A person who was never a party to the agreement is not automatically bound by its terms. Once confidential information has reached a third party, proving the circumstances of receipt and preventing further dissemination may become more difficult.
That does not necessarily leave the information without legal protection. Section 6 of the Commercial Torts Law addresses misappropriation of trade secrets, including certain circumstances in which a person receives or uses a secret knowing, or where it is apparent, that the information has been transferred through prohibited conduct. A non-signatory may therefore face liability under the statute even though no contractual NDA claim can be brought against that person.
Foreign counsel assessing a disclosure or misuse involving Israel should distinguish the contractual claim against a party to the NDA from the separate statutory claim for misappropriation. The evidence and legal elements are not necessarily the same.
What should an NDA identify and regulate?
The agreement should identify the confidential information with sufficient precision for the parties to understand what is being disclosed and protected. If the subject matter is described only in very general terms, the recipient may later dispute whether the specific information at issue was ever provided under the agreement. Where appropriate, a description of the technology, documents or commercial material can appear in a schedule or exhibit.
For a cross-border transaction, the drafting should also reflect why the information is being disclosed and what the recipient is allowed to do with it. Matters that commonly require attention include permitted use, onward disclosure to employees and advisers, protective measures, duration, exceptions for information already lawfully known or independently developed, and the handling of materials when discussions end. The choice of governing law and dispute-resolution arrangements may also require particular care when the parties are located in different countries. These are drafting considerations, not a fixed list of mandatory statutory clauses.
The following historical example appeared in the Hebrew article as a unilateral confidentiality undertaking to be signed before a presentation. It is reproduced in English to illustrate the structure of such an undertaking. It is not a current model NDA suitable for execution without legal review and adaptation to the parties, information, permitted use, duration and applicable exceptions.
Historical sample: Confidentiality undertaking before a presentation
I, the undersigned, ____________________, holder of Israeli identity card or company registration number ____________________, of ____________________, hereby undertake towards ____________________ (the “Presenter”) as follows:
1. To maintain in confidence and not to disclose, transfer or provide, by any means and at any time, including before, during or after my business relationship with the Presenter, and whether or not any such relationship is ultimately established, any information relating to an idea presented to me by the Presenter during the presentation, and any information concerning a company established or to be established by the Presenter, its services, customers, plans, professional, business or commercial secrets, or affairs, which comes or may come to my knowledge or to the knowledge of persons acting on my behalf, provided that such information is not in the public domain. If information becomes publicly available as a result of a breach of an undertaking by me, persons acting on my behalf, my agents or my employees, it shall nevertheless remain confidential for the purposes of this undertaking. Such information may include, without limitation, oral or written information, reports, records, documents, maps and descriptions of marketing, distribution, development or other processes, in any form whatsoever (the “Confidential Information”). A copy of the presentation is attached and marked Exhibit A.
2. Not to copy or reproduce the Confidential Information, or permit or cause another person to reproduce, photocopy, print or otherwise make copies of it.
3. To safeguard the Confidential Information carefully and take all precautions necessary to prevent its loss or disclosure to another person.
4. Not to publish or make any use whatsoever of the Confidential Information provided to me, whether directly or through another person.
5. I acknowledge that I shall be required to compensate the Presenter for any damage caused to the Presenter as a result of my breach of the obligations under this undertaking.
6. This undertaking shall remain in effect for as long as the information is confidential and secret and has not entered the public domain.
7. My obligations under this undertaking are irrevocable.
By signing below, I confirm that I have read and understood the terms of this undertaking.
Date: ____________________ Signature: ____________________
Practical considerations before disclosing an invention or trade secret
At an early stage of development, before a patent or design application has been filed, it is generally prudent to address confidentiality with the professionals and other parties who need access to the underlying information. The agreement should be in place before disclosure, and the material actually shared should be identifiable.
Where disclosure is proposed to a commercial party that may also be a potential competitor, confidentiality arrangements should be considered alongside the possibility of securing patent or design protection. A registered intellectual property right may be enforceable against third parties independently of an agreement, whereas an NDA gives rise to contractual obligations between the relevant parties. The distinction matters when choosing how to protect information that may be shared more widely in the future.
When disclosure, an alleged breach or related proceedings concern Israel, the precise terms of the NDA and the requirements of Israeli trade secret law should be assessed together. An NDA is part of the protection strategy, not a substitute for establishing that the information is legally protected.
